Boehringer Ingelheim and Lilly to support new American College of Cardiology program to highlight the increasingly important role of cardiologists in reducing cardiovascular risk and cardiovascular death in people with type 2 diabetes. Boehringer Ingelheim and Eli Lilly and Company announced that the companies will support an American College of Cardiology (ACC) program focused on driving…
Financial Incentives, Physician Awareness, and Regulatory Support Boost Biosimilars Market in Europe
Biosimilars is set to be one of the fastest growing segments of the global pharma industry, with major opportunities across therapeutic areas like rheumatoid arthritis with AbbVie‘s Humira (adalimumab), cancer with Roche‘s Herceptin (trastuzumab), and diabetes with Sanofi‘s Lantus (insulin glargine). The combination of technology related disruptions, emerging clinical requirements, ongoing investments, and new entrants across the industry…
Cold Sore Treatment Developed by Squarex Shown Effective by Immunotherapy Study
Cold sores, which affect one in three Americans, may be effectively treated by a new immunotherapy process, as indicated by results of a 54-patient clinical trial at Massachusetts General Hospital in Boston. The patented therapy was developed by Squarex, LLC, of St. Paul. About a third of people world-wide suffer a cold sore at some…
Astellas Scraps NSCLC Treatment Candidate, Terminating Clinical Trials
What to Expect at CPhI North America & InformEx 2017
Leading pharmaceutical and specialty chemical solution providers highlight innovation at CPhI North America and InformEx 2017. The world’s largest pharmaceutical event series, CPhI, will debut in Philadelphia May 16–18, 2017. This inaugural event is to be held adjacent to the 33rd edition of InformEx, the leading event for the fine and specialty chemicals industry. “Both the pharmaceutical and…
Amazon Top 100 Author to Present at NEXUS 2017 in June
Dr. Bertalan Mesko, “The Medical Futurist” to deliver headline keynote at TraceLink NEXUS 17. TraceLink Inc. announces Dr. Bertalan Mesko, “The Medical Futurist” and Amazon Top 100 author, as a headline keynote speaker at NEXUS 17, taking place June 7 – 8 in Barcelona. As the pharmaceutical industry prepares for the implementation of drug product serialization and fast-approaching regulatory deadlines, such as…
Natural treatment has an antibiotic-like effect on HPV
Natural treatment has an antibiotic-like effect on viruses; CBCD reports publication of a new clinical study of Gene-Eden-VIR/Novirin. Most drugs target symptoms. Antibiotics are different. Antibiotics target the cause of the disease, and as a result, cure the disease. Almost all other drugs, such as those that lower cholesterol or blood pressure, target symptoms. These…
Diamond BioPharm’s Response to the United Kingdom’s Withdrawal from the European Union
BDI Pharma Celebrates World Hemophilia Day
BDI Pharma celebrates World Hemophilia Day; raises money to support World Federation of Hemophilia. On Monday, April 17th, employees of BDI Pharma recognized World Hemophilia Day by joining together in support of the millions of children and adults affected by bleeding disorders. Events were held at the company’s South Carolina, Texas and Kansas locations with remote employees joining in the efforts,…
Cannabics Collaborates with CTC Lab for Tumor Treatments
NCATS Provides Support for R&D Organization’s Pre-Clinical Drug Development & Manufacture Programs
Halal Nutraceuticals & Vaccines Market Projected to Reach $82M by 2026
Immune Enters Research Collaboration to Develop Tumor Treatment
Global Pharma Solvents Market to Grow Only Moderately Through 2026 Due to Stringent Regulations
Phase 1 Trial for Panacea’s Prostate Cancer Vaccine Initiated
Report: Prefilled Syringes Market to Reach $22.5B by 2025
Teewinot Secures U.S. Patent for Biosynthesis of Cannabinoids
Novartis Out-Licenses Three COPD Products in the US
Novartis announced that it has signed a licensing agreement with Sunovion Pharmaceuticals Inc. for the U.S. commercial rights to its three treatments for chronic obstructive pulmonary disease (COPD), Utibron™ Neohaler® (indacaterol/glycopyrrolate) inhalation powder, Seebri™ Neohaler® (glycopyrrolate) inhalation powder, and Arcapta®Neohaler® (indacaterol) inhalation powder. This deal is specific to the U.S. only and has no implications outside this market. Novartis will…
Phase II Results: Novartis’ Breast Cancer Drug in Combination with Letrozole as First-Line Treatment
Lexicon Gets Pain Drug Candidate Rights Under Bristol-Myers Link
Fimbrion and GSK to Develop Novel Antibacterial Therapy for Urinary Tract Infections
Fimbrion Therapeutics, Inc., a start-up biotechnology company focused on developing antibiotic-sparing drugs, has entered into collaboration with GlaxoSmithKline (GSK), a science-led global healthcare company, to develop a small molecule drug for the treatment and prevention of urinary tract infections (UTIs). The agreement creates a joint project between Fimbrion and the Discovery Partnerships with Academia (DPAc) team at…
BERG Collaborates with Department of Defense & Walter Reed National Military Medical Center for Breast Cancer Precision Medicine
First Vaccine Against Cholera Now Available in U.S.
Study: Antiepileptic Drug Can Eliminate Seizures in Dravet Syndrome
Newly published data show Biscayne Pharmaceuticals’ novel antiepileptic drug can eliminate seizures in models of Dravet syndrome. Biscayne Pharmaceuticals, Inc., reported that a new scientific publication1shows that lead compound BIS-001 can eliminate all seizures in the majority of animals in models of the catastrophic type of epilepsy known as Dravet syndrome. BIS-001 is a clinical-stage, highly potent…